newsfilter
← Latest News
GlobeNewswire·

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

-- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND